Hydroxychloroquine Sulfate Zentiva Pharma (Hydroxychloroquine Sulfate)

The drug interferes with the malaria parasite’s ability to detoxify heme by raising the pH inside its digestive vacuole, which is lethal to the parasite. In autoimmune diseases, it dampens immune activation by inhibiting Toll‑like receptors and decreasing cytokine release, thereby reducing inflammation.

The dosage is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and other clinical factors. Healthcare providers determine the appropriate strength and frequency according to current treatment guidelines.

Safety data for hydroxychloroquine in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. Clinicians must weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Hydroxychloroquine offers a favorable safety profile compared with some older antimalarials and certain disease‑modifying agents, but it may act more slowly than newer biologics for rheumatoid arthritis. Its dual activity against malaria and autoimmune disease makes it a versatile choice when both indications are relevant.

Hydroxychloroquine Sulfate Zentiva Pharma should be stored at or below 25 °C in its original packaging, protected from moisture and direct sunlight. Maintaining a stable ambient environment helps preserve tablet integrity and potency.

The medication is taken orally, typically with or without food, as directed by the prescriber. Patients should swallow tablets whole with a full glass of water and follow any specific timing instructions provided by their healthcare professional.

The most concerning adverse events include retinal toxicity leading to irreversible vision loss, cardiomyopathy with potential arrhythmias, and severe cutaneous reactions such as Stevens‑Johnson syndrome. Regular monitoring and prompt reporting of symptoms are essential to mitigate these risks.

Patients with known hypersensitivity to hydroxychloroquine or related compounds, those with pre‑existing retinopathy, significant cardiac conduction abnormalities, or severe hepatic or renal impairment should avoid this medication unless a specialist determines that benefits outweigh risks.